The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Two new drugs will soon be available to target little-known forms of high cholesterol, which are driven by our genes and ...

Experts have started thinking more broadly about what puts a person at risk for heart disease, still the leading killer in the U.S.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

High cholesterol can go undetected for some time before it turns into something much more severe, so what what warning signs should you look out for?

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

Regulating Cholesterol Levels Might Be the Key to Improving Cancer Treatment Apr. 30 ... reveals that immune cells in the liver react to high cholesterol levels and eat up excess cholesterol ...

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart ...